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Plasma membrane calmodulin-dependent calcium AT-
Pases (PMCAs) are enzymatic systems implicated in the
extrusion of calcium from the cell. We and others have
previously identified molecular interactions between the
cytoplasmic COOH-terminal end of PMCA and PDZ do-
main-containing proteins. These interactions suggested a
new role for PMCA as a modulator of signal transduction
pathways. The existence of other intracellular regions in
the PMCA molecule prompted us to investigate the possi-
ble participation of other domains in interactions with
different partner proteins. A two-hybrid screen of a hu-
man fetal heart cDNA library, using the region 652–840 of
human PMCA4b (located in the catalytic, second intra-
cellular loop) as bait, revealed a novel interaction be-
tween PMCA4b and the tumor suppressor RASSF1, a Ras
effector protein involved in H-Ras-mediated apoptosis.
Immunofluorescence co-localization, immunoprecipita-
tion, and glutathione S-transferase pull-down experi-
ments performed in mammalian cells provided further
confirmation of the physical interaction between the two
proteins. The interaction domain has been narrowed
down to region 74–123 of RASSF1C (144–193 in RASSF1A)
and 652–748 of human PMCA4b. The functionality of this
interaction was demonstrated by the inhibition of the
epidermal growth factor-dependent activation of the Erk
pathway when PMCA4b and RASSF1 were co-expressed.
This inhibition was abolished by blocking PMCA/
RASSSF1 association with an excess of a green fluores-
cent protein fusion protein containing the region 50–123
of RASSF1C. This work describes a novel protein-protein
interaction involving a domain of PMCA other than the
COOH terminus. It suggests a function for PMCA4b as an
organizer of macromolecular protein complexes, where
PMCA4b could recruit diverse proteins through interac-
tion with different domains. Furthermore, the functional
association with RASSF1 indicates a role for PMCA4b in
the modulation of Ras-mediated signaling.
Plasma membrane calmodulin-dependent calcium ATPases
(PMCAs)1 are enzymatic high affinity Ca2-extruding systems
that are thought to play a key role in maintaining intracellular
calcium homeostasis in nonexcitable cells (reviewed in Ref. 1).
PMCAs are P-type ATPases (2, 3), characterized by the for-
mation of an aspartyl phosphate intermediate during the reac-
tion cycle. At present, four different PMCA isoforms,
PMCA1–4, have been identified in mammals as the products of
four independent genes (4–10). PMCA1 and PMCA4 are ubiq-
uitously expressed, whereas PMCA2 and PMCA3 show a more
restricted cell- and tissue-specific pattern of expression (5, 10).
The primary protein structure of PMCAs comprises 10 mem-
brane-spanning segments, two major cytosolic loops, and NH2
and COOH cytoplasmic tails. The COOH-terminal tail contains
an autoinhibitory domain (situated 40 amino acids down-
stream of the last transmembrane domain) that binds Ca2-
calmodulin and plays a major role in the regulation of the
activity of the enzyme (11–13). In the absence of Ca2-calmod-
ulin, this domain interacts with two different regions of PMCA
located in the first and second intracellular loops (13, 14). This
intramolecular interaction keeps the pump in an inactive state.
Elevation in the Ca2-calmodulin levels prompts high affinity
binding to the autoinhibitory domain, releasing inhibition, and
stimulating pump activity.
Our group and others have identified other molecular inter-
actions involving the COOH-terminal region and PDZ domain-
containing proteins. These proteins include members of the
membrane-associated guanylate kinase (MAGUK) family (15,
16), cytoskeletal proteins (17), Na/H exchanger regulatory
factor 2 (18), nitric-oxide synthase I (nNOS) (19), calcium/
calmodulin-dependent serine protein kinase (CASK) (20), and a
novel protein named PISP (PMCA-interacting single-PDZ pro-
tein) (21). These interactions suggest a new function of PMCA
as a modulator of intracellular signaling pathways. In fact, by
placing interaction partners in a cellular microenvironment,
where the concentrations of Ca2 and calmodulin are kept low,
PMCA was shown to negatively modulate the activity of nNOS
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(19) and CASK (20). These interactions are dependent on the
presence of the E(T/S)X(V/L)* sequence in the COOH-cytoplas-
mic end of PMCA, and PDZ domains in the partner proteins.
However, the existence of other intracellular domains in the
PMCA polypeptide chain, and the previous reports of a func-
tional interaction between PMCA and calmodulin (a protein
without PDZ domains), prompted us to investigate whether
other regions are implicated in interactions with different part-
ner proteins.
To test this hypothesis, we performed a two-hybrid screen of
a human fetal heart cDNA library. We used the sequence from
amino acids 652 to 840 (located in the catalytic, second intra-
cellular loop, between transmembrane domains 4 and 5) of the
human PMCA4b isoform (accession no. NM_001684) as bait.
A positive clone encoding a partial sequence of the tumor
suppressor RASSF1, a Ras effector protein that mediates the
apoptotic effects of H-Ras (22, 23), was isolated. We have fur-
ther characterized RASSF1 as a novel interaction partner of
PMCA. Interaction of PMCA with RASSF1 significantly inhib-
ited the EGF-dependent activation of the mitogen-activated
protein kinase Erk, indicating a role for PMCA as a modulator
of EGF-mediated Ras signaling pathways via interaction with
RASSF1.
This work shows a novel protein-protein interaction involving
a domain of PMCA other than the COOH terminus. It suggests a
role for PMCA as an organizer of macromolecular protein com-
plexes, and a regulator of intracellular signaling pathways in the
microenvironment of these multiprotein complexes.
EXPERIMENTAL PROCEDURES
Cell Culture, Isolation, and Culture of Neonatal Rat Cardiomyo-
cytes—HEK 293 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10% FCS and 1%
penicillin/streptomycin.
Isolation of neonatal rat cardiomyocytes was performed on hearts
removed from 1–3-day-old rats. Hearts were cut in small pieces and
ventricular tissue digested by several rounds of 10-min incubation in a
filter-sterilized solution of collagenase A (0.3 mg/ml), pancreatin (0.6
mg/ml), ADS buffer, pH 7.35 (0.68% NaCl (w/v), 0.476% Hepes (w/v),
0.012% NaH2PO4 (w/v), 0.1% glucose (w/v), 0.04% KCl (w/v), 0.01%
MgSO4 (w/v)) at 37 °C with shaking. Each round of digestion was
finished by addition of 2 ml of FCS. Digestions were pooled and cells
collected by centrifugation at 700 rpm for 4 min. Cell pellet was resus-
pended in plating media (68% DMEM, 17% Medium 199, 10% horse
serum, 5% FCS) (1 ml/pup), plated on 100  20-mm tissue culture
dishes (Falcon), and incubated for 60 min at 37 °C, 5% CO2 to remove
cardiac fibroblasts. Supernatants containing cardiomyocytes were
plated on 22  22-mm collagen-coated coverslips and further incubated
overnight at 37 °C, 5% CO2 to allow cellular attachment. The following
day, cells were washed with PBS and plating media were replaced with
maintenance media (79.5% DMEM, 19.5% Medium 199, 1% FCS) sup-
plemented with 1% penicillin/streptomycin.
Plasmids—The region encoding amino acids 652–840 of human
PMCA4b was amplified by 35 cycles of PCR (the conditions were dena-
turation at 94 °C for 45 s, annealing at 50 °C for 45 s, and extension at
72 °C for 1 min 30 s) using the oligonucleotides hPMCA4b652Sense (5-
TCTTCgCggATCCTgggACAATgAgAATgAgATC-3) and hPMCA4b840A-
nti (5-TCTTCCgCTCgAggATgCTgTCATAgACATTTCg-3). The ampli-
fied product was digested with BamHI and XhoI and cloned into the
BamHI-XhoI sites of plasmid pBT (Stratagene) to generate plasmid pBT-
hPMCA4b (652–840).
pFlag-RASSF1A wild type and pFlag-RASSF1C (S61F) contain the
cDNAs encoding human RASSF1A and RASSF1C, respectively, fused
to the Flag epitope in a modified pcDNA3 vector in the manner previ-
ously reported (23). RASSF1C (S61F) cDNA was isolated from neurons
derived from a cloned human teratocarcinoma cell line. The sequence of
RASSF1C (S61F) is identical to that of the RASSF1C wild type protein
(accession no. AF132676) except for a mutation in nucleotide 193 (C3
T) that changes serine 61 to phenylalanine.
Site-directed mutagenesis (S131A) of RASSF1A was performed with
a QuikChange kit (Stratagene, La Jolla, CA) using the protocol from the
manufacturer. The oligomers used were: (5-TgggAgACACCAgATCTT-
gCTCAAgCTgAgATTg-3) and (5-CAATCTCAgCTTgAgCAAgATCTgg-
TgTCTCCCT-3). Mutants were identified by the introduction of a silent
BglII site and confirmed by sequencing.
pCMV-hPMCA4b contains the human PMCA4b cDNA and was a gift
from Prof. E. Strehler (Department of Biochemistry and Molecular
Biology, Mayo Clinic, Rochester, MN 55905).
To generate plasmids pGEX-KG-RASSF1C (50–123), pGEX-KG-RA-
SSF1C (124–197), and pGEX-KG-RASSF1C (198–270), fragments en-
compassing nucleotides 159–380, 381–602, and 603–821 (numbering
according to GenBankTM accession no. AF132676) were generated by 35
cycles of PCR (the conditions were denaturation at 94 °C for 30 s,
annealing at 66 °C for 1 min, and extension at 72 °C for 1 min) using
oligonucleotides BamRASSF1Sense50 (5-TCTTCgCggATCCgACgAgC-
CTgTggAgTgggAg-3) and XhoRASSF1Anti123 (5-TCTTCCgCTCgAg-
TCCTgggCCCCgCCgggCATC-3) for amplification of nucleotides 159 to
380, BamRASSF1Sense124 (5-TCTTCgCggATCCCggggCACAAgTgT-
CAggCgC-3) and XhoRASSF1Anti197 (5-TCTTCCgCTCgAgCCgCAg-
gggCTgCTCATCATC-3) for amplification of nucleotides 381 to 602,
and BamRASSF1Sense198 (5-TCTTCgCggATCCCTgCggCTCCTggC-
AgggCCC-3) and XhoRASSF1Anti270 (5-TCTTCCGCTCGAGTCACC-
CAAGGGGGCAGGCGTG-3) for amplification of nucleotides 603–821.
pFlag-RASSF1C (S61F) was used as template in the PCR reactions.
Amplified fragments were cloned into the BamHI-XhoI sites of
pGEX-KG to generate plasmids pGEX-KG-RASSF1C (50–123), pGEX-
KG-RASSF1C (124–197), and pGEX-KG-RASSF1C (198–270), which
encode GST fusion proteins containing RASSF1C (S61F) amino acids
50–123, 124–197, or 198–270, respectively.
To generate plasmids encoding Flag-tagged COOH-terminal deletion
mutants of RASSF1C, fragments encompassing nucleotides 12–158,
12–269, 12–380, or 12–602 (numbering according to GenBankTM acc-
ession no. AF132676) were generated by 35 cycles of PCR (the condi-
tions were denaturation at 94 °C for 30 s, annealing at 56 °C for 1 min,
and extension at 72 °C for 1 min) using oligonucleotides EcoRASSF1S-
ense1 (5-TCTTCCggAATTCCATgggCgAggCggAggCgCC-3) and Bam-
RASSF1Anti49 (5-TCTTCgCggATCCTCACTggTCCCggCgCggCCTgC-
3), BamRASSF1Anti86 (5-TCTTCgCggATCCTCACTTgTTCAAgCTC-
ATgAAgAg-3), BamRASSF1Anti123 (5-TCTTCgCggATCCTCATCCT-
gggCCCCgCCgggCATC-3), or BamRASSF1Anti197 (5-TCTTCgCggA-
TCCTCACCgCAggggCTgCTCATCATC-3), respectively. pFlag-RAS-
SF1C (S61F) was used as a template. Amplified products were digested
with EcoRI and BamHI and cloned into the EcoRI-BamHI sites of
plasmid p3xFlag-CMV7.1 (Sigma-Aldrich). The resulting plasmids
pFlag-RASSF1C (1–49), pFlag-RASSF1C (1–86), pFlag-RASSF1C
(1–123), and pFlag-RASSF1C (1–197) encode Flag-tagged RASSF1C
truncated proteins containing amino acids 1–49, 1–86, 1–123, and
1–197, respectively.
Likewise, to generate Flag-tagged RASSF1C NH2-terminal deletion
mutants, fragments encompassing nucleotides 195–821, 231–821, or
270–821 (according to accession no. AF132676) were generated by 35
cycles of PCR by using the following oligonucleotides: EcoRASSF1S-
ense62 (5-TCTTCCggAATTCCCAAgCTgAgATTgAgCAgAAg-3) and
BamRASSF1Anti270 (5-TCTTCgCggATCCTCACCCAAgggggCAggCg-
Tg-3) for amplification of nucleotides 195–821 (PCR conditions: dena-
turation at 94 °C for 45 s, annealing at 44 °C for 45 s, extension at 72 °C
for 45 s); EcoRASSF1Sense74 (5-TCTTCCggAATTCCgCCCAgATCAA-
CAgCAACCTC-3) and BamRASSF1Anti270 for amplification of nu-
cleotides 231–821 (PCR conditions: denaturation at 94 °C for 45 s,
annealing at 48 °C for 45 s, extension at 72 °C for 45 s); and EcoRAS-
SF1Sense87 (5-TCTTCCggAATTCCgACggTTCTTACACAggCTTC-3)
and BamRASSF1Anti270 for amplification of nucleotides 270–821
(PCR conditions: denaturation at 94 °C for 30 s, annealing at 56 °C for
1 min, extension at 72 °C for 1 min).
pFlag-RASSF1C (S61F) was used as template in the PCR reactions.
Amplified products were digested with EcoRI and BamHI and cloned
into the EcoRI-BamHI sites of plasmid p3xFlag-CMV7.1 (Sigma-
Aldrich). The resulting plasmids, pFlag-RASSF1C (62–270), pFlag-
RASSF1C (74–270), and pFlag-RASSF1C (87–270), encode Flag-tagged
RASSF1C truncated proteins containing amino acids 62–270, 74–270,
and 87–270, respectively.
To generate the plasmid pCMV-MycRASSF1A, the coding sequence
for RASSF1A was subcloned from pFlag-RASSF1A into the BamHI and
XhoI cloning sites of the expression vector pCMV-Tag 3B (Stratagene).
To generate plasmid pFlag-hPMCA4b (652–840), a cDNA fragment
coding for the region of human PMCA4b encompassing amino acids
652–840, was generated by 35 cycles of PCR using the following oligo-
nucleotides and PCR conditions: BamPMCA4bSense652 (5-TCTTCgC-
ggATCCgTgggACAATgAgAATgAgATCC-3) and XhoPMCA4bAnti840
(5-TCTTCCgCTCgAgTCAgATgCTgTCATAgACATTTCgT-3) (PCR
conditions: denaturation at 94 °C for 45 s, annealing at 58 °C for 1 min,
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extension at 72 °C for 1 min 30 s). The amplified fragment was digested
with BamHI and XhoI and cloned into the BglII-XhoI restriction sites of
plasmid p3xFlag-CMV7.1 (Sigma-Aldrich). To generate construct pFl-
ag-hPMCA4b (749–840), the PCR fragment was digested with HindIII
and XhoI and cloned into the HindIII-XhoI sites of plasmid p3xFlag-C-
MV7.1 (Sigma-Aldrich).
To clone pEGFP-R (50–123), the fragment encompassing nucleotides
159–380 of RASSF1C was amplified by 35 cycles of PCR using the oligo-
nucleotides EcoRASSF1Sense50 (5-TCTTCCggAATTCCgACgAgCCTgT-
ggAgTgggAg-3) and BamRASSF1Anti123 (5-TCTTCgCggATCCTCATC-
CTgggCCCCgCCgggCATC-3). PCR conditions were denaturation at
94 °C for 30 s, annealing at 66 °C for 30 s, and extension at 72 °C for 30 s.
pFlag-RASSF1C (S61F) was used as a template in the PCR reactions.
Amplified products were digested with EcoRI and BamHI and cloned into
the EcoRI-BamHI sites of plasmid pEGFP-C1 (Clontech).
The fidelity of all amplified products was confirmed by sequencing.
pFA2-Elk1 (Stratagene) encodes a fusion protein between the DNA
binding domain of the yeast Gal4 protein and the transactivation do-
main of the transcription factor Elk1. pFR-Luc (Stratagene) is a re-
porter vector containing a synthetic promoter with five tandem repeats
of the yeast Gal4-binding sites that control the expression of the lucif-
erase gene.
Two-hybrid Assay—A two-hybrid screen of a BacterioMatchTM hu-
man fetal heart cDNA library (Stratagene) was performed according to
the instructions of a BacterioMatchTM two-hybrid system vector kit
(Stratagene). Approximately 2  106 independent cDNA clones (which
is equivalent to the whole library) were screened and assayed for resist-
ance to carbenicillin or for -galactosidase expression. To test for resist-
ance to carbenicillin, transformed bacteria were plated onto LB-CTCK
(250 g/ml carbenicillin, 15 g/ml tetracycline, 34 g/ml chloramphenicol,
50 g/ml kanamycin) agar plates and incubated at 30 °C for 48 h. To test
for -galactosidase expression, carbenicillin-resistant bacteria were
plated onto LB-X-gal indicator plates (15 g/ml tetracycline, 34 g/ml
chloramphenicol, 50 g/ml kanamycin, 80 g/ml X-gal, 200 M phenyl-
ethyl--D-thiogalactoside) and incubated at 30 °C for 48 h.
Positive clones were sequenced following standard procedures.
Immunofluorescence Experiments—Primary rat neonatal cardiomyo-
cytes were washed with PBS, warmed at 37 °C, and fixed with 2%
paraformaldehyde for 30 min at room temperature. After two washes
with PBS, cardiomyocytes were permeabilized with 0.1% Triton X-100
in PBS for 15 min. Unspecific staining was reduced by blocking with
10% horse serum for 30 min. Cells were incubated overnight with a 1%
(v/v) solution of 5F10 anti-PMCA monoclonal antibody (Neomarkers) in
1% horse serum, and a 2% (v/v) solution of a goat polyclonal anti-
RASSF1 antiserum (C-12, Santa Cruz) in 1% horse serum, and then
washed three times with PBS. Antibody binding was detected by incu-
bation, for 2 h in the dark, with a 1% (v/v) solution of a FITC-conjugated
AffiniPure donkey anti-mouse IgG (Jackson ImmunoResearch) in 1%
horse serum for detection of PMCA, and a 1% (v/v) solution of Texas
Red-conjugated AffiniPure rabbit anti-goat IgG (Jackson Immuno-
Research) in 1% horse serum for detection of RASSF1. Unbound anti-
body was removed by washing three times with PBS.
HEK 293 cells were plated onto 22  22-mm coverslips at a density
of 5  105 cells/coverslip. Transfected cells were washed with PBS,
warmed at 37 °C, and fixed with 2% paraformaldehyde for 30 min at
room temperature. Cells were washed twice with PBS and permeabi-
lized with 0.1% Triton X-100 in PBS for 15 min. Unspecific staining was
reduced by blocking with 10% horse serum for 30 min. Cells were
incubated overnight with a 0.1% (v/v) solution of a rabbit polyclonal
anti-PMCA4 antibody (Swant) in 1% horse serum and a 0.1% solution of
a FITC-conjugated anti-Flag monoclonal antibody (Sigma) in 1% horse
serum. Following incubation, cells were washed three times with PBS.
Antibody binding to PMCA4 was detected by incubation for 2 h in the
dark with a 1% (v/v) solution of a Texas Red dye-conjugated AffiniPure
donkey anti-rabbit (Jackson ImmunoResearch) in 1% horse serum.
Unbound antibody was removed by washing three times with PBS.
Coverslips were mounted in Antifade reagent (Molecular Probes) on
glass slides. Fluorescence was visualized using a Leica DM LB fluores-
cence microscope.
GST Fusion Protein Expression and Pull-down Assays—GST-
RASSF1 fusion proteins were expressed in bacteria by incubation in LB
medium supplemented with 1 mM isopropyl-1-thio--D-galactopyrano-
side and ampicillin (100 g/ml), at 37 °C, for 5 h. Bacterial pellet was
resuspended and sonicated in NET-N buffer (20 mM Tris, pH 8.0, 100
mM NaCl, 1 mM EDTA, pH 8.0, 20 M PMSF, 500 ng/ml leupeptin, 1.0
g/ml aprotinin, 500 ng/ml pepstatin). GST fusion proteins were puri-
fied by incubation with glutathione-agarose beads (Sigma) at 4 °C, for
45 min. After washing three times with NET-N buffer, beads containing
purified GST fusion proteins were resuspended in RIPA buffer (1
PBS, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 20 M PMSF,
500 ng/ml leupeptin, 1.0 g/ml aprotinin, 500 ng/ml pepstatin). Protein
concentration and integrity were detected by PAGE electrophoresis and
subsequent Coomassie Blue staining.
For pull-down assays, cardiac protein extracts were prepared by
homogenization of mouse hearts in RIPA buffer (1 ml/heart). Cardiac
protein extracts were precleared by incubation (4 °C, 60 min) with
glutathione-agarose beads (100 l of agarose beads/1 ml of cardiac
extracts) to avoid unspecific binding. After preclearing, 250 g of car-
diac proteins were incubated with 3 g of GST fusion protein-agarose
beads at 4 °C, overnight. Beads were collected by centrifugation at
3,000 rpm, washed twice with RIPA buffer, and resuspended in 60 l of
2 Laemmli loading buffer. Pulled down proteins were detected by
Western blot.
Transient Transfection—For immunofluorescence assays, HEK 293
cells were plated in 22  22-mm coverslips at a density of 5  105
cells/coverslip the day before transfection. Cells were transfected with 6
g of pCMV-hPMCA4b and 6 g of pFlag-RASSF1A by using Lipo-
fectAMINE 2000 reagent (Invitrogen) according to the instructions
from the manufacturer.
For immunoprecipitation experiments, HEK 293 cells were plated in
100  20-mm tissue culture dishes (4.5  106 cells/plate) the day before
transfection. Cells were transfected in 4 ml of DMEM plus 10% FCS
using 10 g of the indicated expression plasmids by the calcium phos-
phate method. HEK 293 cells were incubated with precipitated DNA for
4.5 h, washed with PBS and incubated for 36 h more at 37 °C in 5 ml of
DMEM plus 10% FCS prior to immunoprecipitation.
For luciferase assays, HEK 293 cells were plated in 6-well tissue
culture plates (7 105 cells/well) the day before transfection. Cells were
transfected with 3.0 g of an expression vector encoding human
PMCA4b (pCMV-hPMCA4b) or the corresponding empty vector
(pcDNA3), 3.0 g of an expression vector encoding RASSF1 (pFlag-
RASSF1A wild type, pFlag-RASSF1A (S131A), or pFlag-RASSF1C
(S61F)) or the corresponding empty vector (pcDNA3-Flag), 0.25 g of
pFA2-Elk1 (Stratagene), and 0.25 g of the luciferase reporter pFR-Luc
(Stratagene) by using LipofectAMINE 2000 reagent (Invitrogen) ac-
cording to the instructions form the manufacturer. When indicated
pEGFP-R (50–123) or the corresponding empty vector (pEGFP-C1) was
included in the transfection reaction. Transfected cells were incubated
with DNA-LipofectAMINE complexes for 24 h, washed once with PBS,
and then incubated overnight in 5 ml of fresh DMEM, 10% FCS. The
next morning, transfected cells were stimulated with epidermal growth
factor (Sigma) (10 ng/ml) and incubated 6 h more. Cell extracts were
prepared, and luciferase activity was determined with a luciferase
assay system (Promega). Transfection efficiency was normalized by
co-transfection of plasmid pEF-LacZ carrying the -galactosidase gene
under the control of the EF1 promoter, and determination of -galac-
tosidase activity (24).
Immunoprecipitation—Transfected HEK 293 cells were lysed with
0.4 ml of RIPA buffer (1 PBS, 1% Igepal, 0.5% sodium deoxycholate,
0.1% SDS, 20 M PMSF, 500 ng/ml leupeptin, 1.0 g/ml aprotinin, 500
ng/ml pepstatin). To minimize unspecific binding, 1.2 ml of protein
extracts were precleared by incubation with 200 l of protein G-agarose
beads (Roche) and 5 l of anti-luciferase polyclonal antibody (1 mg/ml)
(Promega) at 4 °C, for 1 h. Beads were removed by centrifugation at
3,000 rpm, and 550 l of precleared extracts were incubated overnight
with the corresponding immunoprecipitating antibodies and 40 l of
protein G-agarose beads, at 4 °C with shaking. Beads were recovered by
centrifugation at 3,000 rpm and washed three times with 500 l of
RIPA buffer. Washed beads were resuspended in 75 l of 2 Laemmli
loading buffer and analyzed by Western blot.
Western Blot—Samples were boiled and resolved, under reducing con-
ditions, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (6 or
12% polyacrylamide for human PMCA4b or Flag-tagged RASSF1 detec-
tion, respectively). The gels were transferred onto nitrocellulose mem-
branes and blocked with 5% (w/v) skim milk solution in Tris-buffered
saline (TBS) at 4 °C overnight. After being washed in TBS-T (TBS, 0.05%
Tween 20), the membranes were incubated for 2 h at room temperature
with a 0.1% (v/v) solution of JA3 monoclonal antibody (Neomarkers) in
TBS-T for PMCA4b detection, or a 0.1% (v/v) solution of anti-Flag M2
peroxidase-conjugated monoclonal antibody (Sigma-Aldrich) in TBS-T, for
Flag-epitope detection. The membranes were washed three times for 5
min with TBS-T; for PMCA4b detection, membranes were incubated for
2 h at room temperature with a 0.013% (v/v) solution of peroxidase-labeled
goat anti-mouse immunoglobulins (Dako) in TBS-T and washed twice
with TBS-T. Bound antibodies were detected with the ECL Western
blotting detection reagents (Amersham Biosciences).
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RESULTS
Bacterial Two-hybrid Screen Using as Bait Amino Acids
652–840 from Human PMCA4b—The involvement of the
PMCA COOH-terminal domain in binding to PDZ domain-
containing proteins has been well documented (15–21). The
primary protein structure of PMCA comprises two large in-
tracellular regions in addition to the COOH- and NH2-
terminal domains. We reasoned that these regions could be
involved in molecular interactions with proteins different to
those previously described. As a first step to address this
hypothesis, we decided to identify proteins that would bind to
the region 652–840 of the second intracellular loop of human
PMCA4b. This region was chosen because of its high degree
of homology in the other isoforms of PMCA (91, 89.9, and
90.4% amino acid identity with PMCA1, -2, and -3, respec-
tively), as the study of its functionality might provide some
insight into the general function of PMCAs. In this work we
have focused on the characterization of the interaction be-
tween PMCA4b and RASSF1. Whether other isoforms of
PMCA interact with RASSF1 through this region requires
further studies.
The plasmid pBT-hPMCA4b (652–840), expressing a protein
containing the fragment 652–840 of PMCA4b fused to the
full-length bacteriophage cI repressor protein, was used as
bait to screen a BacterioMatchTM human fetal heart cDNA
library (Stratagene). The screening of 2  106 independent
clones yielded positive clones resistant to carbenicillin and
expressing -galactosidase. We and others have previously sug-
gested a role for PMCA as a modulator of signal transduction
pathways via interaction with signaling target proteins such as
members of the MAGUK family (15, 16), nNOS (19), or CASK
(20). Hence, positive clones isolated by two-hybrid screening
were sequenced, and further selected on the basis of their
potential involvement in signal transduction pathways in car-
diac cells. Clone A37 encoded a truncated protein correspond-
ing to the region encompassing amino acids 120–344 of the
tumor suppressor protein RASSF1E (accession no. AF102772).
RASSF1 has recently been characterized as a Ras effector
protein strongly expressed in the heart (23). The Ras pathway
has been shown to be activated in cardiac hypertrophy and
failure (25). Conversely activated Ras overexpression has been
demonstrated to promote cardiac hypertrophy (26). In view of
the potential role of PMCA4b as a signal transduction modu-
lator, the identification of a Ras effector in our interaction
screen was of particular interest. This formed the basis of our
decision to investigate the molecular interaction between
PMCA4b and RASSF1.
RASSF1E is one of at least seven splice variants (1A–1G)
generated by alternative splicing and different promoter us-
age of the RASSF1 gene; 1A and 1C are the two major splice
variants (22, 23). The region of RASSF1E that was pulled
down with PMCA4b contains four amino acids, PILQ (posi-
tions 120–123), which are exclusive to this isoform. The
remaining domain corresponds to an identical region shared
with 1A and 1C (amino acids 120–340 in RASSF1A, 50–270
in RASSF1C) (Fig. 1). This result therefore suggests that
both major isoforms, 1A and 1C, may in fact interact with
human PMCA4b.
Co-precipitation of Human PMCA4b and Human Splice
Variants RASSF1A and RASSF1C in Mammalian Cells—To
confirm the interaction between PMCA4b and RASSF1 in
mammalian cells, we co-transfected HEK 293 cells with the
expression plasmids pCMV-hPMCA4b (encoding human
PMCA4b) and pFlag-RASSF1A (for RASSF1A). Protein ex-
tracts were immunoprecipitated with the anti-PMCA mono-
clonal antibody 5F10. 5F10 was able to co-precipitate PMCA
together with Flag-tagged RASSF1A (Fig. 2A). When cells were
transfected with the pcDNA3-Flag empty vector, the 5F10 an-
tibody precipitated PMCA but not the control Flag protein,
demonstrating the specificity of the interaction (Fig. 2A). Con-
trol immunoprecipitations carried out with an irrelevant anti-
body (anti-luciferase) precipitated no protein at all, confirming
the selectivity of the interaction (Fig. 2A).
Serine 131 in RASSF1A (61 in RASSF1C) has been reported
to play a key role in the functionality of the protein (27). This
residue is part of the motif WETPDLSQAEIEQK (amino acids
125–138 in RASSF1A, 55–68 in RASSF1C), which matches the
ATM family phosphorylation consensus sequence (28). Muta-
tion of serine 131 to phenylalanine has been shown to inhibit
both phosphorylation and RASSF1A-mediated growth arrest
(27). We therefore investigated whether mutation of serine 131
(61 in RASSF1C) had any effect on the interaction of RASSF1
with PMCA4b. For this purpose, we created by site-directed
mutagenesis a mutant version of RASSF1A by substitution of
serine 131 to alanine, RASSF1A (S131A). We also isolated from
a human teratocarcinoma cell line a cDNA encoding a mutant
version of RASSF1C with a substitution of serine 61 to pheny-
lalanine, RASSF1C (S61F).
Immunoprecipitation experiments performed in transfected
HEK 293 cells demonstrated that both RASSF1A wild type and
S131A mutant proteins interacted with human PMCA4b (Fig.
2B). Likewise, RASSF1C (S61F) mutant co-precipitated with
human PMCA4b (Fig. 2B), confirming our initial prediction of
an interaction between PMCA4b and RASSF1C as well as
RASSF1A. Interaction of PMCA4b and the mutant versions of
RASSF1 suggests that serine 131 (61 in 1C), and therefore
RASSF1 phosphorylation, is not required for association with
PMCA4b. Untransfected cells and cells transfected with the
pcDNA3-Flag empty vector were used as negative controls of
the experiments (Fig. 2B).
In summary, these results show a physical interaction be-
tween PMCA4b and the two major splice variants of RASSF1,
and demonstrate in a mammalian context our initial observa-
tion from two-hybrid experiments.
PMCA and RASSF1 Co-localize in Mammalian Cells—To fur-
ther substantiate the physical interaction between PMCA and
RASSF1 in mammalian cells, we co-transfected HEK 293 cells
with the expression plasmids pCMV-hPMCA4b and pFlag-
RASSF1A, and analyzed the localization of the recombinant pro-
teins by immunofluorescence. Ectopic PMCA4b and Flag-
FIG. 1. Identification of RASSF1 as a PMCA4b interaction
partner. The region 652–840 from hPMCA4b was used as bait in a
two-hybrid experiment. One clone, A37, isolated based on its resistance
to carbenicillin and its -galactosidase expression, encoded a truncated
version corresponding to amino acid residues 120–344 of the human
RASSF1E protein. The sequence of this truncated protein is compared
with those of the two major RASSF1 isoforms (RASSF1A and
RASSF1C). Hatched boxes represent identical regions in the RASSF1
sequence pulled out by the two-hybrid screen, and isoforms 1A and 1C.
Gray and black boxes show the divergent NH2-terminal regions of
RASSF1A or 1C, respectively. The numbering is according to accession
nos. AF102770, AF132676, and AF102772 for RASSF1A, -1C, and -1E,
respectively. The white box represents 4 amino acid residues (PILQ)
that are exclusive to isoform 1E.
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RASSF1A were detected by staining with a polyclonal antibody
that specifically recognizes PMCA4 (Swant) and an anti-Flag
monoclonal antibody (Sigma), respectively. PMCA4b was lo-
calized in transfected cells, at the plasma membrane and
forming a meshwork-like pattern in the cytoplasm (Fig. 3A).
RASSF1 showed a similar pattern, localizing at the plasma
membrane and in a cytoplasmic meshwork (Fig. 3A). The
merged image showed co-localization of ectopic PMCA4b and
Flag-RASSF1A (Fig. 3A). Samples incubated only with sec-
ondary antibodies, FITC-conjugated anti-mouse IgG, or
Texas Red-conjugated anti-rabbit IgG did not show any stain-
ing (data not shown), confirming the specificity of the immu-
nofluorescence detection.
Likewise, we analyzed the subcellular localization of the
endogenous proteins in primary rat neonatal cardiomyocytes
by immunofluorescence. PMCA4 and RASSF1 were detected by
staining with 5F10 (a monoclonal antibody that recognizes all
PMCA isoforms), and a polyclonal antiserum raised against
RASSF1, respectively. Endogenous PMCA and RASSF1 also
showed co-localization at the plasma membrane and in a cyto-
plasmic network (Fig. 3B). No staining at these cellular or-
ganelles was detected in control samples incubated only with
secondary antibodies, FITC-conjugated anti-mouse IgG, or
Texas Red-conjugated anti-goat IgG (Fig. 3B). These results
confirm the physical interaction between endogenous PMCA
and RASSF1. The strong fluorescence detected in the perinu-
clear areas of rat neonatal cardiomyocytes cells appears to be
unspecific, as control samples stained only with the secondary
antibodies also showed staining in these areas (Fig. 3B).
Taken together, these results strongly suggest the physical
association of PMCA4 and RASSF1 in mammalian cells.
The Region 74–123 of RASSF1C Is Essential for Interaction
with PMCA4b—Our next aim was to determine the domain of
RASSF1 involved in the interaction with PMCA4b. The re-
sults from two-hybrid and immunoprecipitation experiments
indicated that the RASSF1 interaction domain should be
found in the identical region shared by isoforms 1A and 1C.
Therefore, we generated GST fusion proteins containing
amino acids 50 –123, 124 –197, or 198 –270 of RASSF1C
(S61F) (Fig. 4A) and used them in GST pull-down assays
together with protein extracts isolated from mouse hearts.
GST-RASSF1C (50–123) pulled down endogenous cardiac
PMCA4 (Fig. 4B). PMCA4, however, did not interact with
GST fusion proteins containing regions 124–197 or 198–270
of RASSF1C (Fig. 4B), indicating that the interaction domain
was included within the region 50–123. Absence of interac-
tion in control reactions performed with empty or GST-bound
glutathione-agarose beads demonstrated the specificity of the
assay (Fig. 4B).
To confirm and further characterize the RASSF1 domain
implicated in the interaction with PMCA, we generated a series
of Flag-tagged RASSF1C (S61F) COOH-terminal deletion mu-
tants (Fig. 4C) and assayed by immunoprecipitation their ca-
pacities to interact with human PMCA4b. HEK 293 cells were
co-transfected with pCMV-hPMCA4b and plasmid pFlag-
RASSF1C (1–270), pFlag-RASSF1C (1–197), pFlag-RASSF1C
(1–123), pFlag-RASSF1C (1–86), or pFlag-RASSF1C (1–49),
and protein extracts were immunoprecipitated with the anti-
PMCA monoclonal antibody 5F10. Deletion of the regions 198–
270 or 124–270 of RASSF1C had no effect on the binding of the
RASSF1C mutants to PMCA4b, as 5F10 co-precipitated
PMCA4b and the corresponding RASSF1C truncated proteins
(Fig. 4D, upper panel). However, removal of the region 87–270
in the mutant Flag-RASSF1C (1–86) significantly inhibited the
interaction with PMCA, although a minimal association was
still present (Fig. 4D, upper panel). Further deletion of amino
acids 50–86 in the mutant Flag-RASSF1C (1–49) totally im-
paired its interaction with PMCA4b (Fig. 4D, upper panel).
Immunoprecipitations carried out with an irrelevant antibody
(anti-luciferase) precipitated no protein at all (data not shown),
demonstrating the specificity of the interaction. Untransfected
cells or cells transfected with the pFlag empty vector were used
as negative controls (Fig. 4D). The Flag-tagged RASSF1C (1–
49) mutant was expressed at levels higher than those of the
Flag-RASSF1C (1–270) full-length protein, ruling out the pos-
sibility of poor expression as the reason for lack of interaction
(Fig. 4D, lower panel).
FIG. 2. Human PMCA4b and RASSF1 interact in mammalian
cells. PMCA and Flag-RASSF1 co-precipitate by using a monoclonal
antibody directed against PMCA, demonstrating the physical interac-
tion between the two proteins. A, expression vectors encoding human
PMCA4b (pCMV-hPMCA4b) and a Flag-tagged version of human
RASSF1A (pF-RASSF1A) were co-transfected in HEK 293 cells. Protein
lysates were incubated with an anti-PMCA monoclonal antibody (5F10)
or an irrelevant antibody raised against firefly luciferase (-Luc), and
subsequently protein complexes precipitated with protein G beads.
Western blots of immunoprecipitated proteins were probed with the
JA3 anti-PMCA4b monoclonal antibody or the M2 anti-Flag monoclonal
antibody, to detect PMCA4b (WB: PMCA) or Flag-tagged RASSF1 (WB:
F-RASSF1), respectively. Western blot of cells transfected with empty
vector (pcDNA3-Flag) was used as negative control. B, expression vec-
tors encoding human PMCA4b (pCMV-hPMCA4b) and a Flag-tagged
version of human RASSF1A wild type (pF-RASSF1A), a functionally
defective mutant of RASSF1A (pF-RASSF1A (S131A)), or a functionally
defective mutant of RASSF1C (pF-RASSF1C (S61F)), were co-trans-
fected in HEK 293 cells. Protein lysates were incubated as described
above and analyzed by Western blot. WB: PMCA, detection of PMCA4b;
WB:F-RASSF1, detection of Flag-tagged RASSF1 proteins. Cells left
untransfected, and transfections performed with empty vector
(pcDNA3-Flag) were used as negative controls. RASSF1 mutants co-
precipitated together with PMCA4b, suggesting that serine 131 of
RASSF1A (61 in RASSF1C) is not essential for interaction.
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These results indicate that the region encompassing amino
acids 87–123 plays a major role in the interaction, although
some residues upstream of amino acid 86 must still be in-
volved in the association with PMCA4b and be required for a
maximal interaction.
To investigate this hypothesis, we prepared a series of NH2-
terminal deletion mutants (Fig. 4C) and tested their capabili-
ties for binding to PMCA4b by immunoprecipitation as previ-
ously described. Deletion of the region 1–61 or 1–73 of
RASSF1C did not alter the binding of mutants Flag-RASSF1C
(62–270) or Flag-RASSF1C (74–270) to PMCA4b (Fig. 4E, up-
per panel). Further removal of the amino acids 74–86 in the
mutant Flag-RASSF1C (87–270) resulted in a slight, but sig-
nificant reduction in its interaction with PMCA4b (Fig. 4E,
upper panel), indicating that the region 74–86 is required for
maximal interaction between the two proteins. Levels of the
Flag proteins prior to immunoprecipitation were checked by
Western blot to eliminate ascribing differences to differential
expression (Fig. 4E, lower panel).
In summary, these results demonstrate that the region 74–
123 of RASSF1C is required for a maximal interaction with
PMCA4b.
The Region 652–748 of PMCA4b Is Critical for Interaction
with RASSF1—The two-hybrid assay showed that the region
652–840 of PMCA4b was sufficient to mediate the interaction
with RASSF1. To confirm this result and identify the minimal
domain of PMCA4b that interacts with RASSF1, we generated
plasmids pFlag-hPMCA4b (652–840) and pFlag-hPMCA4b
(749–840) encoding Flag-tagged proteins containing the re-
gions 652–840 and 749–840, respectively (Fig. 5A) of the hu-
man PMCA4b protein. HEK 293 cells were co-transfected with
plasmid pCMV-MycRASSF1A (encoding a Myc-tagged version
of RASSF1A) and plasmid pFlag-hPMCA4b (652–840) or
pFlag-hPMCA4b (749–840). Protein extracts isolated from
transfected cells were immunoprecipitated with an anti-Myc
monoclonal antibody (Invitrogen), and immunoprecipitated
proteins detected by Western blot (Fig. 5B, left panel). As
expected, Flag-PMCA4b (652–840) co-precipitated with
RASSF1A. However, Flag-PMCA4b (749–840) lacking the re-
gion 652–748 of hPMCA4b failed to interact with RASSF1A,
suggesting that the missing region is critical for the interaction
of human PMCA4b and RASSF1A. Immunoprecipitations car-
ried out with an irrelevant antibody (anti-luciferase) precipi-
tated no protein at all (data not shown), demonstrating the
specificity of the interaction. Cells left untransfected were used
as a negative control. Expression of Flag proteins was detected
FIG. 3. RASSF1 and PMCA co-local-
ize in mammalian cells. Double immu-
nofluorescence staining of PMCA and
RASSF1 shows co-localization in mam-
malian cells. A, HEK 293 cells were co-
transfected with the expression vectors
pCMV-hPMCA4b and pFlag-RASSF1A.
The localization of the resulting PMCA4b
or Flag-tagged RASSF1A proteins was de-
tected by incubation with a rabbit poly-
clonal anti-PMCA4 antiserum (Swant)
(left panel) or a FITC-conjugated anti-
Flag monoclonal antibody (Sigma) (mid-
dle panel), respectively. Bound anti-
PMCA4 antibodies were stained by
secondary incubation with a Texas Red
dye-conjugated AffiniPure donkey anti-
rabbit IgG. The merged image (right
panel) shows co-localization of PMCA4
and RASSF1A at the plasma membrane
and forming a meshwork-like pattern in
the cytoplasm. Two representative fields
containing transfected cells are shown. B,
the localization of endogenous PMCA and
RASSF1 proteins was detected by incu-
bating rat neonatal cardiomyocytes with
the 5F10 anti-PMCA monoclonal anti-
body (-PMCA) and an anti-RASSF1 goat
polyclonal antibody (-RASSF1), respec-
tively. Bound antibodies were stained by
secondary incubation with FITC-conju-
gated AffiniPure donkey anti-mouse IgG
or a Texas Red dye-conjugated AffiniPure
rabbit anti-goat IgG, for detection of
PMCA, or RASSF1, respectively. The
merged image shows co-localization of
PMCA and RASSF1 at the plasma mem-
brane and in a cytoplasmic meshwork
structure, suggesting the physical inter-
action of the endogenous proteins. Con-
trol experiments incubated only with sec-
ondary antibodies (lower panel) confirmed
the specificity of the immunofluorescence
detection.
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FIG. 4. Interaction with PMCA maps to the region 75–123 of RASSF1C. A, schematic representation of GST-RASSF1C fusion proteins used
for pull-down assays. Hatched boxes represent identical regions in RASSF1A and RASSF1C. The numbers correspond to RASSF1C amino acids
according to accession no. AF132676. B, GST-RASSF1 pull-down assay performed by incubating 250 g of cardiac proteins with 3 g of GST fusion
protein-agarose beads. Pulled-down proteins were identified by Western blot using a 1:1000 dilution of an anti-PMCA4 polyclonal antibody (Swant)
in 5% skim milk TBS-T. Control reactions were performed by using agarose beads either empty (beads) or coupled to native GST (GST). (50–123),
(124–196), and (197–270) denote pull-down reactions carried out with GST fusion proteins containing the regions 50–123, 124–196, and 197–270,
respectively, of RASSF1C. C, schematic representation of Flag-tagged RASSF1C COOH- or NH2-terminal deletion mutants used for immunopre-
cipitation. Hatched boxes represent identical regions in RASSF1A and RASSF1C. White boxes represent the unique RASSF1C NH2-terminal
domain. The numbers correspond to RASSF1C amino acids according to accession no. AF132676. D, expression vectors encoding hPMCA4b
(pCMV-hPMCA4b) or Flag-tagged COOH-terminal deletion mutants of RASSF1C encoding amino acids 1–197, 1–123, 1–86, or 1–49, were
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by Western blot (Fig. 5B, right panel), confirming the presence
of Flag-PMCA4b (652–840) or Flag-PMCA4b (749–840) in the
immunoprecipitation reactions.
PMCA4b/RASSF1 Interaction Inhibits EGF-dependent Acti-
vation of Erk—The role of the signal transduction molecule Ras
in the EGF-dependent activation of the Erk pathway in mam-
malian cells is well recognized (29). RASSF1 has been de-
scribed as an effector of Ras that binds to its active form
(Ras-GTP) (23). Therefore, we decided to investigate the func-
tional consequences of the interaction between PMCA4b and
RASSF1 on the activity of Erk in cells stimulated with EGF,
using the PathDetect Elk1 trans-reporting system (Strat-
agene). This system is based on the analysis of the transcrip-
tional activity of a reporter protein containing the DNA binding
domain of the yeast Gal4 protein fused to the transactivation
domain of the transcription factor Elk1. Determination of the
transcriptional activity of the reporter provides an indirect
indication of the activation status of the mitogen-activated
protein kinase Erk. HEK 293 cells were transfected with the
luciferase reporter vector pFR-Luc (Stratagene), and the ex-
pression plasmids pFA2-Elk1 (Stratagene), pCMV-hPMCA4b
(for human PMCA4b expression), and/or pFlag-RASSF1A (for
production of RASSF1A wild type). EGF stimulation of trans-
fected cells enhanced luciferase activity between 30- and 60-
fold. As shown in Fig. 6, ectopic expression of hPMCA4b or
RASSF1A alone did not alter Gal4-Elk1 activation in response
to EGF (Fig. 6). However, coexpression of both proteins caused
a significant (p  0.05) reduction in the EGF-mediated activa-
tion of the reporter, suggesting that the interaction of PMCA4b
and RASSF1 partially inhibits the EGF-dependent activation
of the Erk pathway (Figs. 6 and 7).
Confirming this hypothesis, when the RASSF1 functionally
defective mutants RASSF1A (S131A) or RASSF1C (S61F)
were used instead of the wild type protein, Elk activity was
not significantly altered (Fig. 6). Furthermore, blocking
PMCA4b/RASSF1 interaction with an excess of GFP-R (50–
123), a GFP fusion protein containing the RASSF1 interac-
tion domain, reversed the inhibition in the EGF-mediated
activation of Gal4-Elk1, demonstrating the functionality of
the interaction (Fig. 7). In fact, overexpression of GFP-R
(50–123) not only reversed the inhibition because of ectopi-
cally expressed PMCA4b and RASSF1, but further increased
co-transfected in HEK 293 cells. (1–270) corresponds to the full-length protein. Protein lysates were incubated with an anti-PMCA monoclonal
antibody (5F10) and protein complexes precipitated with protein G beads. Untransfected cells and empty vector (pcDNA3-Flag) were used as
negative controls. Flag-RASSF1 immunoprecipitated proteins were detected by Western blot with M2 anti-Flag peroxidase monoclonal antibody
(upper panel). Arrowhead indicates the decrease in the interaction of mutant RASSF1 (1–86) (upper panel), and its expression levels (lower panel),
indicating that the region 87–123 plays a major role in the interaction. Arrow denotes the absence of interaction of mutant RASSF1C (1–49) (upper
panel), and its expression levels (lower panel). Expression levels of the Flag proteins prior to immunoprecipitation were analyzed by Western blot
(lower panel) with M2 anti-Flag peroxidase monoclonal antibody, using 30 l of protein extracts from cells transfected with plasmids pFlag-
RASSF1C (1–270) (full-length) or pFlag-RASSF1C (1–49); 3 l of extracts from cells transfected with pFlag-RASSF1C (1–197) or pFlag-RASSF1C
(1–123); and 15 l of extracts from cells transfected with pFlag-RASSF1C (1–86). E, immunoprecipitation analysis of the interaction between
PMCA4b and a series of NH2-terminal RASSF1C deletion mutants. Conditions were the same as indicated for the COOH-terminal mutants.
62–270, 74–270, and 87–270 indicate Flag-tagged proteins containing the regions 62–270, 74–270, and 87–270 of RASSF1C. Arrow denotes the
slight decrease in interaction with PMCA4b of the mutant RASSF1C (87–270) (upper panel), and its expression levels (lower panel). Protein
expression levels were analyzed as above, using 15 l of protein extracts isolated from transfected cells.
FIG. 5. Interaction with RASSF1 requires the region 652–748 of human PMCA4b. A, schematic representation of Flag-tagged proteins
used for immunoprecipitation. White boxes indicate the region of PMCA4b that has been fused to the Flag tag. The numbers correspond to human
PMCA4b amino acids according to accession no. NM_001684. B, immunoprecipitation analysis of the interaction between RASSF1A and
Flag-tagged proteins containing the regions 652–840 or 749–840 of PMCA4b. Expression vectors encoding Myc-RASSF1A (pCMV-MycRASSF1A)
and Flag-tagged PMCA4b (625–840) or PMCA4b (749–840) were co-transfected in HEK 293 cells. Protein lysates were incubated with an anti-Myc
monoclonal antibody (Invitrogen) and protein complexes precipitated with protein G beads. Untransfected cells were used as a negative control.
Flag-tagged immunoprecipitated proteins were detected by Western blot with M2 anti-Flag peroxidase monoclonal antibody (left panel). The
protein lacking the region 652–748 failed to co-precipitate with RASSF1, indicating the requirement of this region for the interaction. Expression
levels of the Flag proteins prior to immunoprecipitation were analyzed by Western blot (right panel) with M2 anti-Flag peroxidase monoclonal
antibody confirming the presence of Flag-tagged PMCA4b (749–840).
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the transactivation activity of the reporter (Fig. 7), suggest-
ing that GFP-R (50–123) might eliminate some inhibition
because of endogenous PMCA4b and RASSF1 proteins. No
effect was observed in control experiments where native GFP
protein was expressed in excess (Fig. 7).
In summary, these results demonstrate that the physical
interaction between PMCA4b and RASSF1 exerts a negative
modulatory role on EGF-activated Ras signaling pathways.
DISCUSSION
In this work, we describe a novel functional interaction be-
tween PMCA and the tumor suppressor protein RASSF1.
Either ectopically expressed or endogenous PMCA and
RASSF1 co-localized in mammalian cells. RASSF1 localized at
the plasma membrane and in a cytoplasmic meshwork. This
meshwork-like pattern formed by RASSF1 in cardiac cells is
identical to that reported by Liu et al. (30) in mammalian tissue
culture cell lines, and has been reported to be a result of the
association of RASSF1 with the microtubule network. PMCA
co-localization suggests that it might also be associated with the
cytoskeleton network (possibly for intracellular transport), and
in fact, cytoplasmic detection of PMCA has been recently re-
ported by Rivas et al. (31), who showed redistribution of PMCA4
from the cytoplasm to the plasma membrane upon T-cell activa-
FIG. 6. Co-expression of hPMCA4b and RASSF1 inhibits the Erk pathway. 0.25 g of expression vector pFA2-Elk1, 0.25 g of luciferase
reporter pRL-Luc, 3 g of an expression vector encoding hPMCA4b (pCMV-hPMCA4b), and 3 g of a vector producing Flag-tagged RASSF1A (wild
type), Flag-RASSF1A (S131A) (a RASSF1A mutant version where serine 131 has been mutated to alanine), or Flag-RASSF1C (S61F) (a RASSF1C
mutant version where serine 61 has been substituted to phenylalanine) were co-transfected in HEK 293 cells as described under “Experimental
Procedures,” and stimulated with epidermal growth factor (10 ng/ml). 6 h after stimulation, luciferase activity was measured. The EGF-dependent
activation of the luciferase reporter when the empty vectors pcDNA3-Flag and pCDNA3 were co-transfected was taken as base line and assigned
an arbitrary value of 1. The effects of expression of hPMCA4b, and/or RASSF1 wild type or mutant proteins, in the EGF-dependent activation of
the reporter are expressed as luciferase activity relative to the base line. Transfection efficiency was normalized by co-transfection of the pEF-LacZ
plasmid as internal control, and measure of -galactosidase expression. Asterisk denotes statistically significant (p  0.05, according to Student’s
t test) inhibition of the EGF-mediated activation of the Gal4-Elk1 reporter as a result of co-expression of hPMCA4b and RASSF1A wild type.
Means  S.E. of three independent experiments are shown.
FIG. 7. PMCA4b/RASSF1 interac-
tion inhibits the Erk pathway. Trans-
fections, luciferase assays, and data rep-
resentation were as described for Fig. 6,
except that 6 g of pEGFP-C1 (empty vec-
tor) or pEGFP-R (50–123) (a GFP protein
containing the region 50–123 of
RASSF1C (S61F)) were also included in
the transfection reactions. Overexpres-
sion of an excess of EGFP-R (50–123) re-
versed the PMCA/RASSF1-mediated in-
hibition in the EGF-dependent activation
of the Gal4-Elk1 reporter, whereas GFP
overexpression did not have any effect.
This result demonstrates the functional-
ity of the interaction. Means  S.E. of at
least three independent experiments are
shown.
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tion. Moreover, preliminary experiments performed in our labo-
ratory indicate interaction between PMCA and cardiac -tubu-
lin.2 We are currently exploring this possibility.
We have determined that PMCA4b can interact with the two
major splice variants of RASSF1, RASSF1A and -1C, and found
that this interaction requires the region encompassing amino
acids 652–748 of the catalytic domain of PMCA. Our work
describes a novel protein-protein interaction involving a do-
main of PMCA other than the COOH terminus and suggests
that PMCA could function as a molecular scaffold for the as-
sembly of macromolecular complexes by recruiting several pro-
teins through interactions with different domains.
The region of RASSF1 responsible for interacting with
PMCA4b has been mapped within the domain 74–123 of
RASSF1C (144–193 in RASSF1A). These regions are located
within the identical domains shared by the two isoforms, which
is in keeping with our results indicating that both isoforms
interact with PMCA4b. In fact, the mutant Flag-RASSF1C
(1–49), which failed to bind to PMCA4b, only contains the
specific NH2-terminal region of RASSF1C. Moreover, mapping
of the interaction domain at the region 74–123 concurs with
our finding that the integrity of the association with PMCA4b
is unaffected by mutation of serine 61 in RASSF1C.
Ectopic expression of hPMCA4b or RASSF1A alone did not
alter Erk activation in response to EGF. However, co-expres-
sion of both proteins significantly reduced the activity of an
Erk-dependent luciferase reporter plasmid. The lack of effect
observed when only one of the proteins is overexpressed can be
explained as follows. First, endogenous levels of PMCA4b and
RASSF1 are much lower in comparison to ectopically expressed
protein (for example, see Fig. 2B). Second, the Erk inhibition
fundamentally relies on the interaction between PMCA4b and
RASSF1 as a complex at a physical level. Hence, for a given
amount of complex between endogenous PMCA and RASSF1,
the amount that is unbound and therefore available to ectopi-
cally overexpressed protein is negligible and overexpression of
one protein alone will not lead to the formation of new complex.
PMCA and RASSF1 functionally interact at the endogenous
level, leading to a certain degree of inhibition of Erk activity, as
evidenced by the increase in reporter gene activity when the
interaction domain is co-transfected (Fig. 7).
These results strongly suggest a functional role for the in-
teraction between PMCA and RASSF1 in the regulation of the
Erk pathway. Clearly, overexpression models performed in cul-
tured cells represent a preliminary, but necessary step, in
establishing hypotheses which can then be tested in a physio-
logical setting. We are currently investigating the physiological
relevance of the interaction between these two proteins in vivo
using transgenic animal models.
RASSF1 has been implicated in Ras-dependent, caspase-
mediated apoptosis (23), and several studies have indicated a
role for PMCA in apoptosis (32–34). Our results demonstrate
that interaction of PMCA4b and RASSF1 inhibits the activity
of the Erk pathway, a signaling cascade critical for the regula-
tion of cellular proliferation and survival (35). Therefore, one
could speculate that PMCA functions as an organizer of a
macromolecular complex involved in apoptotic signaling by
inhibiting proliferation and promoting cell death. In this con-
text, Bertin et al. have recently described two novel caspase
recruitment domain (CARD)-containing proteins (CARD11 and
CARD14) that belong to the MAGUK family (36). CARD is a
protein module involved in apoptotic signaling through protein
interactions (37). As is the case with other MAGUK family
proteins, CARD11 and CARD14 contain PDZ domains (36), and
may therefore interact with the COOH-terminal PDZ binding
domain of PMCA. If this is the case, PMCA could recruit two
proteins involved in apoptosis through interaction with two
different domains. We are exploring this possibility further in
our laboratory.
Our group and others have demonstrated the location of
PMCA in caveolae (38, 39). In keeping with the role of PMCA as
an assembler and potential regulator of Ca2 in multiprotein
complexes involved in apoptosis, caveolar microdomains have
been suggested to mediate apoptosis. In fact, apoptosis induced
by tumor necrosis factor- has been proven to be dependent on
intact caveolae (40), and the tumor necrosis factor- receptor
and caspase-3 co-localize in caveolar domains (40, 41). Further-
more, cleavage of PMCA pumps by caspases in cells undergoing
apoptosis leads to the inactivation of PMCA and subsequent
cellular necrosis (32, 33) although Paszty et al. (42) have shown
recently that caspase cleavage of the PMCA increases its ac-
tivity. In addition, antisense inhibition of PMCA has been
reported to induce apoptosis (34).
RASSF1 belongs to a gene family of structurally related
proteins characterized by the presence of a Ras association
domain, including the human RASSF1–3 and Nore1 proteins
(22, 23, 43, 44). When the sequence of the RASSF1 domain that
interacts with PMCA4b was compared with the corresponding
domain in RASSF2, we did not find any significant homology in
that region. However, as well as RASSF1, human RASSF2
promotes apoptosis and cell cycle arrest (44). Interestingly,
RASSF1 binds to H-Ras (23), whereas RASSF2 binds mainly to
K-Ras and only interacts very weakly with H-Ras (44). Disrup-
tion of caveolae by expression of a dominant-negative caveolin
has been reported to inhibit H-Ras- but not K-Ras-mediated
signal transduction (45). Additionally, it is thought that H-Ras
preferentially localizes to lipid rafts/caveolae, whereas K-Ras
shows a less specific pattern of localization and it is found
throughout the plasma membrane (46). This raises the attrac-
tive possibility of the specific involvement of caveolar PMCA in
H-Ras-mediated signaling through association with RASSF1.
In summary, our results demonstrate a novel functional inter-
action between PMCA and RASSF1, suggesting a role for PMCA
as an organizer, and potential regulator of Ca2, in macromolec-
ular signal transduction complexes. Moreover, these results lead
to new testable hypotheses of the molecular mechanisms involv-
ing PMCA in the regulation of apoptotic signaling.
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